LA ATENCIÓN CLÍNICA DE LAS ENFERMEDADES RARAS: UN RETO PARA LA EDUCACIÓN MÉDICA

  • Fernando Suárez-Obando Pontificia Universidad Javeriana
Palabras clave: enfermedades raras, educación médica, Genética Médica, BioInfomática, Investigación en Medicina Traslacional

Resumen

La comprensión de las enfermedades raras, ha permitido el desarrollo de esquemas de tratamiento y aplicación de biotecnología de punta que han sustentado el desarrollo de la Medicina traslacional, la cual apunta tanto a la comprensión de las enfermedades de baja prevalencia como a la aplicación de conocimientos de ciencias básicas para el diagnóstico y tratamiento de las enfermedades más comunes. El enfoque de las enfermedades raras le plantea a la Medicina, diversos retos conceptuales que deben ser afrontados por los currículos de las facultades. El presente artículo describe los desafíos que tiene la educación médica, frente a la enseñanza de las enfermedades raras, teniendo en cuenta que es un área de la Medicina que cobra mayor importancia en la atención clínica y que representa conceptos fundamentales de la asistencia sanitaria contemporánea, como la medicina traslacional y la medicina personalizada. Así mismo, se enfatiza que los adelantos diagnósticos y terapéuticos derivados del estudio de las enfermedades raras, influenciarán diversas áreas de la Medicina, señalando que, a pesar de la particularidad y baja prevalencia de estas enfermedades, su influencia va más allá del ejercicio efectivo del derecho a la salud por parte de un grupo de pacientes.

Biografía del autor/a

Fernando Suárez-Obando, Pontificia Universidad Javeriana
Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana. Servicio de Genética, Hospital Universitario San Ignacio.

Citas

1. Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. Intractable Rare Dis Res. 2012;1(1):3-9.
2. Aronson JK. Rare diseases and orphan drugs. Br J Clin Pharmacol. 2006;61(3):243-5.
3. Rare Diseases Act of 2002. Public Law 107-280 2002 [Available from: https://www.gpo.gov/fdsys/pkg/PLAW107publ280/html/PLAW-107publ280.htm.
4. Haffner ME, Whitley J, Moses M. Two decades of orphan product development. Nat Rev Drug Discov. 2002;1(10):821-5.
5. Forman J, Taruscio D, Llera VA, Barrera LA, Cote TR, Edfjall C, et al. The need for worldwide policy and action plans for rare diseases. Acta Paediatr. 2012;101(8):805-7.
6. Franco P. Orphan drugs: the regulatory environment. Drug Discov Today. 2013;18(3-4):163-72.
7. Dallari S. Fornecimento do medicamento pós-estudo em caso de doenças raras: conflito ético. Revista Bioética. 2015;23(2).
8. Congreso de Colombia. Ley 1438 de 2011. Por medio de la cual se reforma el Sistema General de Seguridad Social en Salud y se dictan otras disposiciones. 2011.
9. Bavisetty S, Grody WW, Yazdani S. Emergence of pediatric rare diseases: Review of present policies and opportunities for improvement. Rare Dis. 2013;1:e23579.
10. Barrera LA, Galindo GC. Ethical aspects on rare diseases. Adv Exp Med Biol. 2010;686:493-511.
11. Gulbakan B, Ozgul RK, Yuzbasioglu A, Kohl M, Deigner HP, Ozguc M. Discovery of biomarkers in rare diseases: innovative approaches by predictive and personalized medicine. EPMA J. 2016;7:24.
12. Litterman NK, Rhee M, Swinney DC, Ekins S. Collaboration for rare disease drug discovery research. F1000Res. 2014;3:261.
13. Camp KM, Krotoski D, Parisi MA, Gwinn KA, Cohen BH, Cox CS, et al. Nutritional interventions in primary mitochondrial disorders: Developing an evidence base. Mol Genet Metab. 2016;119(3):187-206.
14. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1723-32.
15. Beck M. Treatment strategies for lysosomal storage disorders. Dev Med Child Neurol. 2018;60(1):13-8.
16. Fishman MC, Porter JA. Pharmaceuticals: a new grammar for drug discovery. Nature. 2005;437(7058):491-3.
17. Morales-Piga A, Garcia Ribes M, Arribas Alvaro P, Casado Alvaro C, Posada de La Paz M, Bachiller-Corral J. [Is there a place in primary care for rare diseases? The case of fibrodysplasia ossificans progressiva]. Aten Primaria. 2013;45(6):324-8.
18. Senior T, Knight A. Rare diseases: a role for primary care. Lancet. 2008;372(9642):890.
19. Pariser AR, Gahl WA. Important role of translational science in rare disease innovation, discovery, and drug development. J Gen Intern Med. 2014;29 Suppl 3:S804-7.
20. Thevenon J, Duffourd Y, Masurel-Paulet A, Lefebvre M, Feillet F, El ChERadER-Djebbar S, et al. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole-exome sequencing as a first-line diagnostic test. Clin Genet. 2016;89(6):700-7.
21. Basel D, McCarrier J. Ending a Diagnostic Odyssey: Family Education, Counseling, and Response to Eventual Diagnosis. Pediatr Clin North Am. 2017;64(1):265-72.
22. Lazaridis KN, Schahl KA, Cousin MA, Babovic-Vuksanovic D, Riegert-Johnson DL, Gavrilova RH, et al. Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic: The Mayo Clinic Experience. Mayo Clin Proc. 2016;91(3):297-307.
23. Potter BK, Chakraborty P, Kronick JB, Wilson K, Coyle D, Feigenbaum A, et al. Achieving the “triple aim” for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence framework. Genet Med. 2013;15(6):415-22.
24. Hawkes CP, Walsh A, O’Sullivan S, Crushell E. Doctors’ knowledge of the acute management of Inborn Errors of Metabolism. Acta Paediatr. 2011;100(3):461-3.
25. Camp KM, Lloyd-Puryear MA, Yao L, Groft SC, Parisi MA, Mulberg A, et al. Expanding research to provide an evidence base for nutritional interventions for the management of inborn errors of metabolism. Mol Genet Metab. 2013;109(4):319-28.
26. Zand DJ, Brown KM, Lichter-Konecki U, Campbell JK, SalERi V, Chamberlain JM. Effectiveness of a clinical pathway for the emergency treatment of patients with inborn errors of metabolism. Pediatrics. 2008;122(6):11915.
27. Camp KM, Lloyd-Puryear MA, Huntington KL. Nutritional treatment for inborn errors of metabolism: indications, regulations, and availability of medical foods and dietary supplements using phenylketonuria as an example. Mol Genet Metab. 2012;107(1-2):3-9.
28. Leonard JV, Morris AA. Diagnosis and early management of inborn errors of metabolism presenting around the time of birth. Acta Paediatr. 2006;95(1):6-14.
29. Valayannopoulos V, Poll-The BT. Diagnostic work-up in acute conditions of inborn errors of metabolism and storage diseases. Handb Clin Neurol. 2013;113:1553-62.
30. Grosse SD, Wordsworth S, Payne K. Economic methods for valuing the outcomes of genetic testing: beyond costeffectiveness analysis. Genet Med. 2008;10(9):648-54.
31. Lopez-Bastida J, Oliva-Moreno J. Cost of illness and economic evaluation in rare diseases. Adv Exp Med Biol. 2010;686:273-82.
32. Winter SC, Buist NR. Inborn errors of metabolism: medical and administrative “orphans”. Am J Manag Care. 1998;4(8):1164-8.
33. Novoa MC, Burnham TF. [Challenges for the universalization of clinical genetics: the Brazilian case]. Rev Panam Salud Publica. 2011;29(1):61-8.
34. Paez P, Suarez-Obando F, Zarante I. [Genetic diseases in pediatric patients hospitalised in the town of Ubate, Colombia]. Rev Salud Publica (Bogota). 2008;10(3):41422.
35. Rolfo C, Caglevic C, Bretel D, Hong D, Raez LE, Cardona AF, et al. Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. ESMO Open. 2016;1(4):e000055.
36. de la Fuente J, Martuscelli J, Alarcón–Segovia D. El futuro de la investigación médica en México. Gac Méd Méx 2004;40(5):519-24.
37. Kalergis AM, Lacerda M, Rabinovich GA, Rosenstein Y. Challenges for Scientists in Latin America. Trends Mol Med. 2016;22(9):743-5.
38. Zúñiga J. La enseñanza de las ciecnias básicas en medicina desde la perspectiva de la justificación epistemológica del curriculo. Educación. 2009;33(2).
39. Bellgard MI, Sleeman MW, Guerrero FD, Fletcher S, Baynam G, Goldblatt J, et al. Rare Disease Research Roadmap: Navigating the bioinformatics and translational challenges for improved patient health outcomes. Health Policy and Technology. 2014;3(4):325-35.
40. Benitez-Paez A, Cardenas-Brito S. [Bioinformatics in Colombia: state of the art and perspectives]. Biomedica. 2010;30(2):170-7.
41. Weber SL, Segal S, Packman W. Inborn errors of metabolism: psychosocial challenges and proposed family systems model of intervention. Mol Genet Metab. 2012;105(4):537-41.
42. Baldovino S, Moliner AM, Taruscio D, Daina E, Roccatello D. Rare Diseases in Europe: from a Wide to a Local Perspective. Isr Med Assoc J. 2016;18(6):359-63.
43. Feltmate K, Janiszewski PM, Gingerich S, Cloutier M. Delayed access to treatments for rare diseases: who’s to blame? Respirology. 2015;20(3):361-9.
44. Jamiolkowski D, Kolker S, Glahn EM, Baric I, Zeman J, Baumgartner MR, et al. BERavioural and emotional problems, intellectual impairment and health-related quality of life in patients with organic acidurias and urea cycle disorders. J Inherit Metab Dis. 2016;39(2):231-41.
45. República de Colombia. Ministerio de la Protección Social. Ley 1392 de 2010. 2010.
46. República de Colombia. Ley 1098 de 2006. Por la cual se expide el Código de la Infancia y la Adolescencia. 2006.
47. S FN, A JFC. Ética de la equidad y justicia en el acceso al diagnóstico, tratamiento y rERabilitación de los pacientes con enfermedades raras. Revista Médica Clínica Las Condes. 2015;26(4):527-32.
48. McCabe C, Edlin R, Round J. Economic considerations in the provision of treatments for rare diseases. Adv Exp Med Biol. 2010;686:211-22.
49. Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74.
50. Buchanan J, Wordsworth S, Schuh A. Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics. 2013;14(15):1833-47.
51. Potter BK, Khangura SD, Tingley K, Chakraborty P, Little J. Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research? Genet Med. 2016;18(2):117-23.
52. Pagidas K, Ying Y, Keefe D. Predictive value of preimplantation genetic diagnosis for aneuploidy screening in repeated IVF-ET cycles among women with recurrent implantation failure. J Assist Reprod Genet. 2008;25(23):103-6.
53. Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol. 2014;4(3):163-88.
54. Galton DJ, Galton CJ. Francis Galton: and eugenics today. J Med Ethics. 1998;24(2):99-105.
55. Institute of Medicine (US) Committee on Accelerating Rare Diseases Research and Orphan Product Development. Profile of Rare Diseases Washington (DC): National Academies Press (US); 2010 [Available from: https://www.ncbi.nlm.nih.gov/books/NBK56184/.
56. Correa C, Mallarino C, Pena R, Rincon LC, Gracia G, Zarante I. Congenital malformations of pediatric surgical interest: prevalence, risk factors, and prenatal diagnosis between 2005 and 2012 in the capital city of a developing country. Bogota, Colombia. J Pediatr Surg. 2014;49(7):1099-103.
57. Bernal J, Zarante I. [Malformations and congenital anomalies: impact and future]. Biomedica. 2009;29(1):7-8.
58. Battista RN, Blancquaert I, Laberge AM, van Schendel N, Leduc N. Genetics in health care: an overview of current and emerging models. Public Health Genomics. 2012;15(1):34-45.
59. Emery J, Watson E, Rose P, Andermann A. A systematic review of the literature exploring the role of primary care in genetic services. Fam Pract. 1999;16(4):426-45.
60. Wilson BJ, Islam R, Francis JJ, Grimshaw JM, Permaul JA, Allanson JE, et al. Supporting genetics in primary care: investigating how theory can inform professional education. Eur J Hum Genet. 2016;24(11):1541-6.
61. Epstein CJ. Medical genetics in the genomic medicine of the 21st century. Am J Hum Genet. 2006;79(3):434-8.
62. Qureshi N, Modell B, Modell M. Timeline: Raising the profile of genetics in primary care. Nat Rev Genet. 2004;5(10):783-90.
63. Bernal J, Suárez-Obando F. La era genómica y proteómica de la medicina. Univ Méd 2007;48(2).
64. StrannEReim H, Wedell A. Exome and genome sequencing: a revolution for the discovery and diagnosis of monogenic disorders. J Intern Med. 2016;279(1):3-15.
65. Ussher JR, Elmariah S, Gerszten RE, Dyck JR. The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease. J Am Coll Cardiol. 2016;68(25):2850-70.
66. Lam MP, Ping P, Murphy E. Proteomics Research in Cardiovascular Medicine and Biomarker Discovery. J Am Coll Cardiol. 2016;68(25):2819-30.
67. Coughlin SS. Toward a road map for global -omics: a primer on -omic technologies. Am J Epidemiol. 2014;180(12):1188-95.
68. Herr TM, Bielinski SJ, Bottinger E, Brautbar A, Brilliant M, Chute CG, et al. A conceptual model for translating omic data into clinical action. J Pathol Inform. 2015;6:46.
69. Devuyst O, Knoers NV, Remuzzi G, Schaefer F, Board of the Working Group for Inherited Kidney Diseases of the European Renal A, European D, et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet. 2014;383(9931):1844-59.
70. Knox SS. From ‘omics’ to complex disease: a systems biology approach to gene-environment interactions in cancer. Cancer Cell Int. 2010;10:11.
71. Gligorijevic V, Malod-Dognin N, Przulj N. Integrative methods for analyzing big data in precision medicine. Proteomics. 2016;16(5):741-58.
72. Underwood JC. More than meets the eye: the changing face of histopathology. Histopathology. 2017;70(1):4-9.
73. Marincola FM. Translational Medicine: A two-way road. J Transl Med. 2003;1(1):1.
74. Swinney DC, Xia S. The discovery of medicines for rare diseases. Future Med Chem. 2014;6(9):987-1002.
75. Groft SC. Rare diseases research: expanding collaborative translational research opportunities. Chest. 2013;144(1):16-23.
76. Everett JR. From Metabonomics to Pharmacometabonomics: The Role of Metabolic Profiling in Personalized Medicine. Front Pharmacol. 2016;7:297.
77. Sankar PL, Parker LS. The Precision Medicine Initiative’s All of Us Research Program: an agenda for research on its ethical, legal, and social issues. Genet Med. 2016.
78. Adams SA, Petersen C. Precision medicine: opportunities, possibilities, and challenges for patients and providers. J Am Med Inform Assoc. 2016;23(4):787-90.
79. Singh G, Schulthess D, Hughes N, Vannieuwenhuyse B, Kalra D. Real world big data for clinical research and drug development. Drug Discov Today. 2017.
80. Luscombe NM, Greenbaum D, Gerstein M. What is bioinformatics? A proposed definition and overview of the field. Methods Inf Med. 2001;40(4):346-58.
81. Suarez-Obando F, Ordoñez A. Aspectos éticos de la informática médica: principios de uso y usuario apropiado de sistemas computacionales en la atención clínica. Acta Bioethica. 2012;18(2):199-208.
82. Lorenzi NM. The cornerstones of medical informatics. J Am Med Inform Assoc. 2000;7(2):204-5.
83. Suarez-Obando F, Gómez-Restrepo C, Camacho J, de la Hoz A, Ruiz A, Maldonado P, et al. Portal de Guías de Práctica Clínica: estrategia digital (e-learning) para la difusión de guías de práctica desarrolladas en Colombia Desarrollo de una estrategia educativa y de difusión de Guías desarrolladas en Colombia. Univ Méd. 2016;57(1).
84. Belle A, Thiagarajan R, SoroushmERr SM, Navidi F, Beard DA, Najarian K. Big Data Analytics in Healthcare. Biomed Res Int. 2015;2015:370194.
85. Tenenbaum JD. Translational Bioinformatics: Past, Present, and Future. Genomics Proteomics Bioinformatics. 2016;14(1):31-41.
86. Butte AJ, Ohno-Machado L. Making it personal: translational bioinformatics. J Am Med Inform Assoc. 2013;20(4):595-6.
87. Day S. Evidence-based medicine and rare diseases. Adv Exp Med Biol. 2010;686:41-53.
88. Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. J Clin Epidemiol. 2011;64(10):1085-94.
89. Abrahamyan L, Feldman BM, Tomlinson G, Faughnan ME, Johnson SR, Diamond IR, et al. Alternative designs for clinical trials in rare diseases. Am J Med Genet C Semin Med Genet. 2016;172(4):313-31.
90. Kalita-de Croft P, Al-EjER F, McCart Reed AE, Saunus JM, Lakhani SR. ‘Omics Approaches in Breast Cancer Research and Clinical Practice. Adv Anat Pathol. 2016;23(6):356-67.
91. Fragoulakis V, Mitropoulou C, van Schaik RH, Maniadakis N, Patrinos GP. An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine. OMICS. 2016;20(5):27482.
92. Knoppers BM, Leroux T, Doucet H, Godard B, Laberge C, Stanton-Jean M, et al. Framing genomics, public health research and policy: points to consider. Public Health Genomics. 2010;13(4):224-34.
93. Frieden TR. SHATTUCK LECTURE: The Future of Public Health. N Engl J Med. 2015;373(18):1748-54.
94. Llamas B, Willerslev E, Orlando L. Human evolution: a tale from ancient genomes. Philos Trans R Soc Lond B Biol Sci. 2017;372(1713).
95. Cousineau J, Girard N, Monardes C, Leroux T, Jean MS. Genomics and public health research: can the state allow access to genomic databases? Iran J Public Health. 2012;41(5):13-30.
96. Wilkinson JR, Ells LJ, Pencheon D, Flowers J, Burton H. Public health genomics: the interface with public health intelligence and the role of public health observatories. Public Health Genomics. 2011;14(1):35-42.
97. Gjesing AP, Pedersen O. ‘Omics’-driven discoveries in prevention and treatment of type 2 diabetes. Eur J Clin Invest. 2012;42(6):579-88.
98. Taruscio D, Vittozzi L, Choquet R, Heimdal K, Iskrov G, Kodra Y, et al. National registries of rare diseases in Europe: an overview of the current situation and experiences. Public Health Genomics. 2015;18(1):20-5.
99. Vittozzi L, Gainotti S, Mollo E, Donati C, Taruscio D. A model for the European platform for rare disease registries. Public Health Genomics. 2013;16(6):299-304.
100. Lautenschlager R, Kohlmayer F, Prasser F, Kuhn KA. A generic solution for web-based management of pseudonymized data. BMC Med Inform Decis Mak. 2015;15:100.
101. Viviani L, Zolin A, MERta A, Olesen HV. The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry. Orphanet J Rare Dis. 2014;9:81.
102. Kinkorova J. Biobanks in the era of personalized medicine: objectives, challenges, and innovation: Overview. EPMA J. 2015;7:4.
103. Singh V, Braddick D, Dhar PK. Exploring the potential of genome editing CRISPR-Cas9 technology. Gene. 2017;599:1-18.
104. Zomer HD, Vidane AS, Goncalves NN, Ambrosio CE. Mesenchymal and induced pluripotent stem cells: general insights and clinical perspectives. Stem Cells Cloning. 2015;8:125-34.
Publicado
2018-06-28
Sección
Artículos de reflexión